Purpose Head and neck cancers (HNC) are commonly treated with radiation and platinum-based chemotherapy, which produce bulky DNA adducts to eradicate cancerous cells. Because nucleotide excision repair (NER) enzymes remove adducts, variants in NER genes may be associated with survival among HNC cases both independently and jointly with treatment. Methods Cox proportional hazards models were used to estimate race-stratified (White, African American) hazard ratios (HRs) and 95 % confidence intervals for overall (OS) and disease-specific (DS) survival based on treatment (combinations of surgery, radiation, and chemotherapy) and 84 single nucleotide polymorphisms ( Conclusions Our study, a large and extensive evaluation of SNPs in NER genes and HNC survival, identified mostly null associations, though a few variants were suggestively associated with survival and potentially interacted additively with treatment.
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Background
An estimated 53,640 incident head and neck cancer (HNC) cases and 11,520 associated deaths occured in the United States during 2013 [1] . Comprising tumors of the oral cavity, pharynx, and larynx, HNC is a relatively fatal disease [2, 3] . Among individuals with oral and pharyngeal cancers in the United States, five-year survival rates are 61.7 and 63.2 % for White men and women, respectively, and 37.2 and 51.2 % for African American men and women, respectively [2, 3] . HNC was historically treated with surgery and/or radiation [4, 5] . However, following a series of clinical trials in the 1990s, advanced tumors (stages 3 and 4) are increasingly treated with concurrent or induction radiation and chemotherapy [4, 5] . Other tumor characteristics (e.g., location and size) and the patients' demographics (e.g., age) can also influence treatment decisions and outcomes [6] .
Emerging literature suggests that genetic factors may also impact treatment response and survival among cancer patients [7, 8] . In order to initiate cell death (apoptosis) of cancerous cells, radiation and platinum-based chemotherapy are known to cause bulky DNA adducts, among other types of DNA damage [7, 9] . Since nucleotide excision repair (NER) is the pathway primarily responsible for removing DNA adducts, functional NER processes may lessen the efficacy of cancer treatment [7] . This hypothesis has led some researchers to describe DNA repair, including NER, as a ''double-edged sword'' or ''Janus, the two-faced Roman god,'' since functional genes are thought to protect against cancer incidence, but may mitigate the effectiveness of cancer treatments thus decreasing survival [7] .
Although it is hypothesized that the effects of NER variants on survival may be dependent on treatment, previous epidemiologic studies on the effects of single nucleotide polymorphisms (SNPs) in NER genes and treatment on HNC mortality have been inconsistent [9] [10] [11] [12] [13] [14] [15] [16] [17] . For example, some studies conducted among patients receiving radiation reported null associations for rs13181 in excision repair cross-complementing 2 (ERCC2) and survival [9, 12] . Other studies showed evidence for significant differences in survival across genotypes of rs13181 [10, 14, 15] , including a study which found the referent genotype (AA) was associated with worse survival among individuals treated with radiation and better survival among those not receiving radiation [17] . However, previous studies have been based on small sample sizes, predominantly European-descent populations, and a limited number of variants in NER genes [9] [10] [11] [12] [13] [14] [15] [16] [17] . The present study extends the literature by estimating main and joint effects of treatment (combinations of surgery, radiation, and chemotherapy) and 84 SNPs across 15 NER genes on survival in a large, racially diverse group of HNC cases.
Methods

Study population
The Carolina Head and Neck Cancer Epidemiology (CHANCE) Study is a population-based case-control study of 1,389 cases and 1,396 controls from North Carolina (NC) [18] [19] [20] [21] [22] . For the present analysis, we compared survival among cases by treatment and genotype. All cases were 20-80 years of age and were identified from the NC Central Cancer Registry between 1 January 2002 and 28 February 2006 using rapid case ascertainment [18] [19] [20] [21] [22] . Cases with tumors in the oral cavity, oropharynx, hypopharynx, larynx, and HNC not otherwise specified (NOS) were included, while tumors of the salivary glands, nasopharynx, nasal cavity, and nasal sinuses were excluded [18] [19] [20] [21] [22] . Self-reported demographic and behavioral information and biologic samples (*90 % blood, *10 % buccal cells) were collected during a nurse-administered interview [18] [19] [20] [21] [22] . We excluded cases who self-reported race other than White or African American (n = 26, 1.9 %) because of sparse data, as well as lip cancers (n = 21, 1.3 %) because of etiologic differences. Cases who did not provide a biologic sample were also excluded; this comprised 52 cases (3.7 %) who were deceased at time of interview (i.e. proxy interviews) and eight cases (0.6 %) who provided in-person interviews but no biologic sample. Finally, cases whose samples were insufficient for genotyping or whose samples did not otherwise meet quality control criteria (n = 55, 4.0 %) were excluded. Our analysis included 1,227 HNC cases (922 White cases and 305 African American cases).
SNP selection and genotyping
Illumina GoldenGate assay with Sentrix Array Matrix and 96-well standard microtiter plates was used for genotyping [20] [21] [22] [23] . As described previously [22] , 71 tag SNPs in eight NER genes were selected based on a case-control study of HNC at The University of Texas MD Anderson Cancer Center (r 2 C 0.80, minor allele frequency (MAF) C 0.05, 1-2 kb flanking region, CEU population) and 58 SNPs in 12 NER genes were selected based on other cancer studies and/or potential function (Online Resource 1). Of the 129 NER SNPs, variants with poor signal intensity or genotype clustering (14 SNPs) or a MAF less than 0.05 (30 SNPs among Whites and 36 SNPs among African Americans) were excluded (Online Resource 1) [21] [22] . The majority of excluded SNPs were candidate SNPs selected based on previous literature or function (Online Resource 1). Genotype frequencies for the remaining SNPs were consistent with Hardy-Weinberg equilibrium (HWE) among CHANCE controls at a Bonferroni-corrected 0.0006 alpha level, and scatter plots showed reasonable clustering; therefore, no SNPs were excluded for HWE violations [22] . Our analysis included 84 SNPs in 14 NER genes among Whites and 79 SNPs in 15 NER genes among African Americans.
Treatment
First-course treatment information was abstracted from patients' medical records. Information included whether the patient received surgery, radiation, and chemotherapy, including types of chemotherapy drugs: carboplatin, paraplatin, cisplatin, 5-FU, taxol, taxotere, docetaxel, paclitaxel, ifosfamide, and other [21] . Information on treatment start and end dates and whether radiation and chemotherapy were administered concurrently was not available for a large proportion of individuals. Therefore, combinations of treatment were generated from dichotomous variables for surgery, radiation, and chemotherapy regardless of timing. Information on tumor histology and stage was also abstracted from medical records [21] . Tumor grade was not uniformly available for all cases and therefore not considered.
HNC survival CHANCE data were linked to the National Death Index (NDI) based on name, social security number, date of birth, sex, race, and state of residence to identify deaths through 2009, including date of death, location of death, and cause of death [21, 24] . Death records with HNC listed as an underlying cause of death were considered disease-specific deaths. For overall survival models, follow-up started at date of diagnosis for all cases and ended at date of death for individuals who died, or censoring on 31 December 2009 for individuals who were still alive [21] . For disease-specific survival models, follow-up started at date of diagnosis for all cases and ended at date of death for individuals who died of HNC, or censoring at date of death for individuals who died from causes other than HNC or 31 December 2009 for individuals who were still alive [21] .
Statistical analysis
Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for the independent and joint effects of treatment and SNPs on HNC survival among Whites and African Americans separately. To evaluate the proportionality of hazards, we examined adjusted log-negative log plots by treatment and by genotype separately. In addition, we assessed the significance of including an interaction term for time and treatment or genotype in models. If log-negative log plots indicated a violation of the proportional hazards assumption and interaction terms with time were significant (p \ 0.05), accelerated failure time (AFT) models were fit to explore robustness of results. This was the case for four SNPs in Whites (rs3731068, rs744154, rs3136085, and rs3136172) and three SNPs in African Americans (rs4150360, rs2020955, and rs13181). However, because p values for the AFT models were similar to those obtained from Cox models (i.e., the same set of significant SNP-HNC survival associations resulted from both approaches), results from the Cox models without an interaction term between SNPs and time are presented for simplicity. Absolute differences in HNC survival by treatment or genotype were also assessed via Kaplan-Meier plots, with cumulative survival calculated as the proportion of cases alive at each time point and log rank tests used to assess differences in survival.
Treatment
Treatment was modeled as a categorical variable with six groups: surgery only; radiation only; surgery and radiation; radiation and chemotherapy; surgery, radiation, and chemotherapy; and other (no treatment, chemotherapy only, or surgery and chemotherapy without radiation). Surgery only was used as the referent category because few individuals received no treatment (n = 9, 0.7 %). Even fewer individuals received chemotherapy only or chemotherapy with surgery without radiation (n = 4, 0.3 %), so these individuals were combined with individuals receiving no treatment into a single category labeled ''other treatment.'' In a separate model, we also considered receiving platinum-based chemotherapy drugs (carboplatin, paraplatin, or cisplatin, n = 464) versus not receiving platinum-based chemotherapy drugs (i.e., not receiving chemotherapy, n = 754, or only receiving non-platinum-based chemotherapy drugs, including 5 FU, taxol, taxotere, docetaxel, paclitaxel, or ifosfamide, n = 9). All treatment models were stratified by race and adjusted for sex, age (categorical), tumor stage (stages I, II, III, IV), tumor site (oral cavity, oropharynx, hypopharynx, larynx, NOS), education (high school or less, some college, and college or more), duration of cigarette smoking (years), and lifetime consumption of alcohol (categorical milliliters of ethanol).
SNPs
In agreement with previous CHANCE publications [22] , SNPs were defined using a dominant genetic model and the We also considered joint effects models for SNPs and platinum-based chemotherapy which included three disjoint indicator variables (no platinum-based chemotherapy, variant genotype; platinum-based chemotherapy, referent genotype; and platinum-based chemotherapy, variant genotype) and were adjusted for the covariates previously mentioned plus surgery (yes/no) and radiation (yes/no). Interactions between SNPs and treatments were assessed on the additive scale using the relative excess risk for interaction (RERI) with 95 % CIs calculated using the Hosmer and Lemeshow method [29] . Statistical analyses were performed using SAS 9.3 (Cary, NC) [30] .
Results
Demographics
Of the 1,227 HNC cases in CHANCE, 545 (44.4 %) linked with the NDI through 2009 ( Table 1 ). The remaining 682 (55.6 %) were assumed to be alive as of 31 December 2009. The median and mean follow-up times were 919.7 and 764.0 days, respectively, among individuals who died and 2,137.4 and 2,086.0 days, respectively, among those who were alive. Among the 545 cases who died, just under half (n = 227, 41.7 %) had HNC listed as an underlying cause of death. Among these disease-specific deaths, the median and mean follow-up times were 729.7 and 594.0 days, respectively. Modest variation by sex was observed when comparing cases who were living and dead after study follow-up (Table 1) . However, a higher proportion of cases who died were diagnosed between 65 and 80 years of age (38.5% vs. 25.9%),were African American (29.7 vs. 21.0 %) or had a high school education or less (71.9 vs. 53.1 %) compared to living cases. With respect to tumor site, similar proportions had a diagnosis of laryngeal cancer (36.1 %). In contrast, 23.5 % of cases who died had oropharyngeal cancer compared to 30.1 % of cases who were living. As expected [31, 32] , the distribution of tumor stage also varied by survival status, with living cases tending to have lower tumor stage.
Treatment
Among Whites, individuals who received only radiation tended to have worse overall (HR = 1.59, 95 % CI = 1.08, 2.34) and disease-specific survival (HR = 2.47, 95 % CI = 1.34, 4.56) compared to individuals who were treated with surgery alone (Table 2) . Individuals receiving ''other'' treatment (i.e. no treatment, chemotherapy only or chemotherapy and surgery) also appeared to have poorer overall and disease-specific survival, though estimates were imprecise since they were based on few individuals (data not shown). In a separate model, receiving platinum-based chemotherapy appeared to be associated with better overall (HR = 0.71, 95 % CI = 0.52, 0.95 among Whites and HR = 0.77, 95 % CI = 0.48, 1.20 among African Americans) and disease-specific survival (HR = 0.63, 95 % CI = 0.41, 0.97 among Whites and HR = 0.45, 95 % CI = 0.19, 1.02 among African Americans) ( Table 2) . SNPs Among Whites, four SNPs were modestly associated with only overall survival and three SNPs were modestly associated with both overall and disease-specific survival at an uncorrected 0.05 alpha level (Table 3) . However, after correcting the alpha level using the Bonferroni and FDR methods, no SNPs were statistically significantly associated with either outcome. Among the SNPs associated with both outcomes at an uncorrected 0.05 alpha level, two tag SNPs were in linkage disequilibrium (LD) (r 2 = 0.92, CEU population) on ERCC4, also known as xeroderma pigmentosum F (XPF) [33] . Specifically, rs3136038 (TT ? TC vs. CC) and rs3136130 (TT ? GT vs. GG) were suggestively associated with a similarly reduced hazards of overall (HR = 0.79, uncorrected 95 % CI = 0.65, 0.97 and HR = 0.78, uncorrected 95 % CI 0.64, 0.96, respectively) and disease-specific death (HR = 0.69, uncorrected 95 % CI = 0.51, 0.93, and HR = 0.68, uncorrected 95 % CI = 0.50, 0.92, respectively). In addition, rs50871 (TT ? TC vs. CC), a tag SNP on ERCC2 also known as XPD, was suggestively associated with decreased hazards of overall (HR = 0.80, uncorrected 95 % CI = 0.64, 1.00) and disease-specific death (HR = 0.67, uncorrected 95 % CI = 0.48, 0.92). Stratifying by tumor stage, associations for rs3136038 or rs3136130 and survival were strongest among stage four cases and rs50871 among stage three cases (Online Resource 2). Figure 1 shows Kaplan-Meier plots for these SNPs.
Among African Americans, two SNPs were associated with overall survival and four SNPs were associated with disease-specific survival at an uncorrected 0.05 alpha level, but none were significantly associated with survival at Bonferroni-corrected or FDR-corrected levels (Table 4) . Only one tag SNP was associated with both overall and disease-specific survival at an uncorrected 0.05 alpha level. Specifically, rs2607755 (CC ? CT vs. TT) on XPC was suggestively associated with reduced hazards of overall (HR = 0.62, uncorrected 95 % CI = 0.45, 0.86) and disease-specific death (HR = 0.51, uncorrected 95 % CI = 0.30, 0.86). This association was strongest among cases with stage 4 tumors (Online Resource 2). Figure 2 shows Kaplan-Meier plots for this SNP.
Joint effects
At an uncorrected 0.05 alpha level, four SNPs appeared to interact super-additively with radiation only, six SNPs appeared to interact super-additively with radiation and chemotherapy, and one SNP appeared to interact sub-additively with surgery, radiation, and chemotherapy, with respect to overall survival among Whites (Online Resource 3). Of these suggestive interactions, one SNP-radiation and two SNPradiation, chemotherapy interactions were significant at a Bonferroni-corrected 0.0006 alpha level. Specifically, rs2972388 of cyclin-dependent kinase 7 (CDK7) interacted super-additively with radiation only (RERI = 1.07, uncorrected 95 % CI = 0.55, 1.60) and with radiation and chemotherapy (RERI = 0.72, uncorrected 95 % CI = 0.33, 1.10). In addition, rs2974752 of RAD23 homolog A (RAD23A) interacted super-additively with radiation and chemotherapy (RERI = 0.80, uncorrected 95 % CI = 0.36, 1.24). However, when disease-specific survival was considered, no SNP-treatment interactions were significant at a Bonferroni or FDR level among Whites (data not shown). Among African Americans, no SNP-treatment interactions appeared to be significant at a Bonferroni-corrected alpha level with respect to overall survival, though a super-additive interaction between rs1902658 of XPC and radiation, chemotherapy was significant when FDR was considered (RERI = 0.75, uncorrected 95 % CI = 0.29, 1.21). However, interaction estimates among African Americans were considered unreliable due to relatively low cell counts and are therefore not presented. With platinum-based chemotherapy, 10 SNPs suggested additive interactions at an uncorrected alpha level with respect to overall survival among Whites, but none were significant after correction for multiple comparisons (Online Resource 4).
Discussion
We detected mostly null associations between 84 SNPs in 15 NER genes and survival among White and African American HNC cases. Identifying null associations is important for following-up early positive associations, avoiding publication bias, and informing future metaanalyses [34] . To account for multiple comparisons, we principally used the Bonferroni approach, which though widely used in genetic epidemiology assumes independence of tests [25, 35, 36] . Given the correlated nature of SNPs, including some SNPs in our study, using the Bonferroni correction may be overly conservative potentially resulting in false negatives [25, 35, 36] . Therefore, we also considered the FDR approach as well as highlighted SNPsurvival associations with p values below an uncorrected 0.05 alpha level as suggestive associations warranting further investigation.
Among Whites, we found that rs3136038 (near the 5' end) and rs3136130 (intron 5) of ERCC4 were suggestively associated with improved overall and disease-specific survival [37, 38] . These SNPs are in LD with each other as well as several other untyped SNPs near or in introns or the 3 0 UTR of ERCC4 (r 2 [ 0.80, CEU population) [33] . rs50871 of ERCC2 intron 11 was also suggestively associated with improved survival among Whites [37, 38] . Among African Americans, rs2607755, which is located in intron 2 of XPC and is in LD with other intronic SNPs and the missense SNP rs2227998 (Arg687Ser, r 2 = 0.86, YRI population), was suggestively associated with improved overall and disease-specific survival [33, 37, 38] . The ERCC4 enzyme helps create an incision at the 5 0 end of DNA adducts, while ERCC2 operates as a component of the transcription factor II H (TFIIH) subunit to denature the double helix in preparation for incisions [39, 40] . The XPC enzyme acts early in the NER pathway to recognize and bind with DNA adducts [39, 40] . Assuming that it is minor alleles which mitigate functional NER effects, thereby facilitating cancer treatment effects, one may expect variant genotypes of intronic SNPs, especially SNPs in regulatory regions or in LD with SNPs in coding regions, to be associated with improved survival, as was suggested by our findings for rs3136038, rs3136130, and rs50871 among Whites and rs2227998 among African Americans.
Although no previous HNC studies examined rs3136038 or rs3136130 on ERCC4, two studies assessed nine other ERCC4 SNPs (rs1799799, rs1799801, rs3136105, rs3136146, rs3136152, rs3136155, rs3136166, rs3136189, rs3136202), many of which were in LD with the SNPs in our study (r 2 [ 0.80, CEU population) [10, 16, 33] . While five of these SNPs were not associated with progression-free survival among HNC cases, four SNPs appeared to be associated with worse progression-free survival contrary to our study [10, 16] . Among esophageal cancer cases, a study by Lee et al. [41] did assess rs3136038 reporting better overall survival associated with the genotype TT, though HRs were not statistically significant, similar to our study. Further, ERCC4 protein expression has been found to be elevated in HNC cell lines and displayed cisplatin resistance [42] . With respect to ERCC2, no previous studies have considered the effects of rs50871 on HNC survival. Rather, rs13181 and rs1799793 (which are not in LD with rs50871, CEU population) are the most commonly studied SNPs in ERCC2, with some studies reporting near null associations between these SNPs and survival among HNC cases [9, 10, 12, 14, 15, 33] . In our study, rs13181 was not associated with survival. Finally, no previous studies have considered associations between rs2607755 of XPC and survival, nor have any studies considered association between any NER variants and survival among African American HNC cases. Only one previous study has investigated a single variant in XPC, rs2228001 (which is not in LD with rs2607755, YRI population), noting no association with overall survival [9, 33] . Likewise, we did not find an association between rs2228001 and survival. Since radiation and platinum-based chemotherapy are known to cause DNA damage repaired by NER genes [7, 9] , we also considered associations between SNPs and survival among HNC cases in the context of treatment. Accounting for multiple comparisons using the Bonferroni method, we found that interactions between rs2972388, a synonymous SNP in CDK7, and radiation only, as well as radiation and chemotherapy, were more than additive with respect to overall survival among Whites [37, 38] . In addition, rs2974752, located near RAD23A and in LD with other SNPs near or in introns of this gene (r 2 [ 0.80, CEU population), interacted super-additively with radiation and chemotherapy [33, 37, 38] . However, these SNP-treatment interactions were not significant at a Bonferroni level when disease-specific survival was considered and should therefore be interpreted with some caution. Further, genotype frequencies for rs2972388 and rs2974752 were consistent with HWE at a Bonferroni-corrected 0.0006 alpha level, but not at a 0.05 alpha level. 0.05 alpha level. No previous studies have considered CDK7 or RAD23A SNPs in relation to treatment and HNC survival. Only one previous study has compared NER SNP-survival associations across strata of treatment regimens [17] . Specifically, Zhong et al. [17] analyzed the effect of rs13181 in ERCC2 on survival among 275 HNC cases receiving radiotherapy and 210 cases not receiving radiotherapy. Among cases with stage 3 and 4 tumors, the referent genotype (AA) was associated with poorer overall survival among those treated with radiation, but better survival among those who did not receive radiation [17] . Among cases with stage 1 and 2 tumors who did not receive radiation, rs13181 was not associated with survival [17] . With a population-based study of 1,227 HNC cases, the present analysis included more than double the number of HNC cases of the next largest study [10] . Study populations of previous publications were mostly hospital-based and ranged from 47 to 531 HNC cases [10, 13] . Further, the present study population included 922 White cases and 305 African Americans cases which allowed for estimation of race-specific HRs. Linkage disequilibrium is known to vary by ancestral populations and distinct differences in survival by race occur in the United States [2, 3, 33] . Yet, prior to this study, no studies had considered NER SNP-survival associations among African American HNC cases. Another contribution of our study was the broad evaluation of NER variants which included a large number of SNPs that have not been previously evaluated. Previous studies have collectively examined approximately 18 SNPs in six NER genes and survival among HNC cases [9] [10] [11] [12] [13] [14] [15] [16] [17] . Our study included 84 SNPs across 15 NER genes.
Although our study included the largest study population and broadest array of NER SNPs to date to our knowledge, a few limitations should be noted. We were unable to include proxy interviews (52 cases, 3.7 %) in our analysis since these occurred for individuals who died prior to interview and therefore did not provide a biologic sample. If SNPs were related to aggressive tumors, then estimates for SNP-survival associations may be slightly attenuated to the null [21] . When SNP-survival associations were stratified by stage, associations were strongest among cases with stage 3 and 4 tumors. Further, follow-up was started at date of diagnosis, rather than date of interview (i.e., date of blood draw), since diagnosis is a more clinically informative time point. To assess the potential immortal person-time bias this may have introduced [43] , we conducted sensitivity analyses with follow-up starting at date of interview. No material differences in results were noted across models, though rs50871 was suggestively associated with overall survival among Whites with an unadjusted p value of 0.05 in the primary analysis, but with a p value of 0.06 in the sensitivity analysis, and the interaction between rs1902658 and radiation, chemotherapy with respect to overall survival among African Americans was significant at an FDR level in the primary analysis, but at a Bonferroni level in the sensitivity analysis.
Other potential limitations include the following. First, because both tagging and candidate SNPs were included and selected based on European-descent populations, variation captured across some genes was limited, especially among African Americans. For this reason, haplotypes were not explored. Second, treatment was considered solely as the first-course combinations of dichotomous variables for surgery, radiation, and chemotherapy abstracted from medical records. Although treatment is fairly standardized based on tumor stage and site as well as other patient demographics [4, 5] , information on duration of treatment (e.g., start and end dates) and timing of treatments combinations (e.g., concurrent chemotherapy) may have been informative. Third, treatment-SNP joint effect estimates were imprecise among Whites and unreliable among African Americans due to small cell counts. Fourth, models were adjusted for cigarette and alcohol information that was ascertained at baseline based on behaviors prior to diagnosis since information on behavioral risk factors following diagnosis was not uniformly available. Further, we did not have information on human papillomavirus infection, a known predictor of survival among cases with oropharyngeal tumors [44] . Finally, we did not have access to information on recurrent tumors and In summary, most NER variants did not appear to be associated with survival among HNC cases. However, three SNPs in Whites (rs3136038 and rs3136130 of ERCC4 and rs50871 of ERCC2) and one SNP among African Americans (rs2607755 of XPC) were suggestively associated with better overall and disease-specific survival. Therefore, it is recommended that future genetic epidemiology studies of HNC survival include these SNPs for replication. In addition, two SNPs appeared to possibly interact additively with radiation with or without chemotherapy among Whites. While our study is the largest to date, it is only the second to consider NER SNP-treatment joint effects on HNC survival. Therefore, additional studies with even larger sample sizes are needed to evaluate geneenvironment interactions more precisely. Further studies focusing on African American and other diverse populations are recommended.
